Financhill
Buy
93

RBOT Quote, Financials, Valuation and Earnings

Last price:
$17.50
Seasonality move :
-15.83%
Day range:
$14.75 - $18.97
52-week range:
$4.27 - $21.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.63x
Volume:
173.3K
Avg. volume:
54.2K
1-year change:
28.21%
Market cap:
$94.5M
Revenue:
--
EPS (TTM):
-$10.42

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RBOT
Vicarious Surgical
-- -$2.69 -- -42.36% $11.75
CATX
Perspective Therapeutics
$257.8K -$0.26 -- -70.12% $16.15
INFU
InfuSystems Holdings
$34.9M $0.06 9.85% 1713.24% $14.13
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RBOT
Vicarious Surgical
$16.00 $11.75 $94.5M -- $0.00 0% --
CATX
Perspective Therapeutics
$3.53 $16.15 $238.6M -- $0.00 0% 19.06x
INFU
InfuSystems Holdings
$8.32 $14.13 $176.9M 131.42x $0.00 0% 1.35x
RVP
Retractable Technologies
$0.75 -- $22.3M -- $0.00 0% 0.58x
VTAK
Catheter Precision
$0.56 -- $4.5M 0.64x $0.00 0% 1.49x
XTNT
Xtant Medical Holdings
$0.51 -- $71.3M -- $0.00 0% 0.60x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RBOT
Vicarious Surgical
-- 1.805 -- --
CATX
Perspective Therapeutics
-- -3.977 -- --
INFU
InfuSystems Holdings
33.51% 2.491 19.66% 1.37x
RVP
Retractable Technologies
1.55% -0.169 11.72% 5.80x
VTAK
Catheter Precision
12% -4.376 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 0.300 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RBOT
Vicarious Surgical
-- -$17.8M -- -- -- -$12.7M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$19M $3.3M 1.77% 2.8% 9.23% $6.4M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Vicarious Surgical vs. Competitors

  • Which has Higher Returns RBOT or CATX?

    Perspective Therapeutics has a net margin of -- compared to Vicarious Surgical's net margin of --. Vicarious Surgical's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RBOT
    Vicarious Surgical
    -- -$2.90 --
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About RBOT or CATX?

    Vicarious Surgical has a consensus price target of $11.75, signalling downside risk potential of -26.56%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Vicarious Surgical, analysts believe Perspective Therapeutics is more attractive than Vicarious Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RBOT
    Vicarious Surgical
    1 2 0
    CATX
    Perspective Therapeutics
    8 1 0
  • Is RBOT or CATX More Risky?

    Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

  • Which is a Better Dividend Stock RBOT or CATX?

    Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RBOT or CATX?

    Vicarious Surgical quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Vicarious Surgical's net income of -$17.1M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RBOT
    Vicarious Surgical
    -- -- -- -$17.1M
    CATX
    Perspective Therapeutics
    19.06x -- -- -$15.1M
  • Which has Higher Returns RBOT or INFU?

    InfuSystems Holdings has a net margin of -- compared to Vicarious Surgical's net margin of 5.12%. Vicarious Surgical's return on equity of -- beat InfuSystems Holdings's return on equity of 2.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    RBOT
    Vicarious Surgical
    -- -$2.90 --
    INFU
    InfuSystems Holdings
    53.92% $0.08 $83.5M
  • What do Analysts Say About RBOT or INFU?

    Vicarious Surgical has a consensus price target of $11.75, signalling downside risk potential of -26.56%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 69.77%. Given that InfuSystems Holdings has higher upside potential than Vicarious Surgical, analysts believe InfuSystems Holdings is more attractive than Vicarious Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RBOT
    Vicarious Surgical
    1 2 0
    INFU
    InfuSystems Holdings
    4 0 0
  • Is RBOT or INFU More Risky?

    Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.098%.

  • Which is a Better Dividend Stock RBOT or INFU?

    Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RBOT or INFU?

    Vicarious Surgical quarterly revenues are --, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Vicarious Surgical's net income of -$17.1M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 131.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 1.35x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RBOT
    Vicarious Surgical
    -- -- -- -$17.1M
    INFU
    InfuSystems Holdings
    1.35x 131.42x $35.3M $1.8M
  • Which has Higher Returns RBOT or RVP?

    Retractable Technologies has a net margin of -- compared to Vicarious Surgical's net margin of -18.58%. Vicarious Surgical's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    RBOT
    Vicarious Surgical
    -- -$2.90 --
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About RBOT or RVP?

    Vicarious Surgical has a consensus price target of $11.75, signalling downside risk potential of -26.56%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Vicarious Surgical has higher upside potential than Retractable Technologies, analysts believe Vicarious Surgical is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    RBOT
    Vicarious Surgical
    1 2 0
    RVP
    Retractable Technologies
    0 0 0
  • Is RBOT or RVP More Risky?

    Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.939, suggesting its more volatile than the S&P 500 by 93.884%.

  • Which is a Better Dividend Stock RBOT or RVP?

    Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios RBOT or RVP?

    Vicarious Surgical quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Vicarious Surgical's net income of -$17.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RBOT
    Vicarious Surgical
    -- -- -- -$17.1M
    RVP
    Retractable Technologies
    0.58x -- $10.3M -$1.9M
  • Which has Higher Returns RBOT or VTAK?

    Catheter Precision has a net margin of -- compared to Vicarious Surgical's net margin of -4291.67%. Vicarious Surgical's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    RBOT
    Vicarious Surgical
    -- -$2.90 --
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About RBOT or VTAK?

    Vicarious Surgical has a consensus price target of $11.75, signalling downside risk potential of -26.56%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 257.14%. Given that Catheter Precision has higher upside potential than Vicarious Surgical, analysts believe Catheter Precision is more attractive than Vicarious Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RBOT
    Vicarious Surgical
    1 2 0
    VTAK
    Catheter Precision
    0 0 0
  • Is RBOT or VTAK More Risky?

    Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

  • Which is a Better Dividend Stock RBOT or VTAK?

    Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RBOT or VTAK?

    Vicarious Surgical quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Vicarious Surgical's net income of -$17.1M is lower than Catheter Precision's net income of -$4.1M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 1.49x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RBOT
    Vicarious Surgical
    -- -- -- -$17.1M
    VTAK
    Catheter Precision
    1.49x 0.64x $96K -$4.1M
  • Which has Higher Returns RBOT or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Vicarious Surgical's net margin of -17.98%. Vicarious Surgical's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    RBOT
    Vicarious Surgical
    -- -$2.90 --
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About RBOT or XTNT?

    Vicarious Surgical has a consensus price target of $11.75, signalling downside risk potential of -26.56%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 338.43%. Given that Xtant Medical Holdings has higher upside potential than Vicarious Surgical, analysts believe Xtant Medical Holdings is more attractive than Vicarious Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RBOT
    Vicarious Surgical
    1 2 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is RBOT or XTNT More Risky?

    Vicarious Surgical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

  • Which is a Better Dividend Stock RBOT or XTNT?

    Vicarious Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vicarious Surgical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RBOT or XTNT?

    Vicarious Surgical quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Vicarious Surgical's net income of -$17.1M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Vicarious Surgical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vicarious Surgical is -- versus 0.60x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RBOT
    Vicarious Surgical
    -- -- -- -$17.1M
    XTNT
    Xtant Medical Holdings
    0.60x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 High Dividend Dow Jones Stocks
3 High Dividend Dow Jones Stocks

Thanks to surging stock prices over the past two years,…

Will American Tower Stock Recover?
Will American Tower Stock Recover?

The performance of the real estate investment trust, or REIT,…

Will Booking Holdings Stock Split?
Will Booking Holdings Stock Split?

Booking Holdings, the travel and technology company that owns brands…

Stock Ideas

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 125x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
50
NARI alert for Jan 7

Inari Medical [NARI] is up 22.12% over the past day.

Buy
70
PDEX alert for Jan 7

Pro-Dex [PDEX] is down 7.63% over the past day.

Buy
52
ALCO alert for Jan 7

Alico [ALCO] is up 0.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock